1. Perica K, Varela JC, Oelke M, Schneck J. Adoptive T cell immunotherapy for cancer. Rambam Maimonides Med J. 2015;6(1):e0004.
2. Tisagenlecleucel STN 125646 Approval Letter. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Aug 2017. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/kymriah-tisagenlecleucel. Accessed 30 Jan 2021.
3. Axicabtagene Ciloleucel STN BL 125643 Approval Letter. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Oct 2017. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/yescarta-axicabtagene-ciloleucel. Accessed 30 Jan 2021.
4. Brexucabtagene Autoleucel STN BL 125703 Approval Letter. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Jul 2020. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/tecartus-brexucabtagene-autoleucel. Accessed 30 Jan 2021.
5. Lisocabtagene Maraleucel STN BLA 125714 Approval Letter. U.S. Food and Drug Administration, Center for Biologics Evaluation and Research. Feb 2021. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/breyanzi-lisocabtagene-maraleucel. Accessed 6 Feb 2021.